Gossamer Bio (GOSS) Earnings Date & Reports

Key Takeaways

• Gossamer Bio is expected to report its third-quarter 2026 results in early November 2026, with consensus pointing to another quarterly net loss.
• Investors are watching for updates on the regulatory path for seralutinib, the company's lead candidate for pulmonary arterial hypertension (PAH).
• The company's cash runway into the first quarter of 2027 and its proposed convertible debt restructuring remain central concerns.
• A 1-for-80 reverse stock split completed in September 2026 complicates year-over-year per-share comparisons.
• Recent quarters have seen revenue consistently exceed consensus, driven by collaboration-related cost-sharing payments, though EPS has been mixed relative to estimates.
• For more on GOSS, explore its Major News, Today's Price Move, Price Targets, and Forecast.
• Explore Trending AI Robots to discover data-driven trading ideas across the market.

Earnings Context and Why It Matters

Gossamer Bio is a clinical-stage biopharmaceutical company focused on seralutinib, an inhaled therapy in development for PAH, a serious lung condition. This earnings report carries unusual weight because it arrives shortly after several structural changes: the company reacquired worldwide rights to seralutinib, completed a workforce reduction affecting roughly half of its employees, and pursued a debt exchange to strengthen its balance sheet. With top-line data from the Phase 3 PROSERA study already public and a New Drug Application (NDA) submission targeted for September 2026, the third-quarter update offers investors a fresh look at the company's cash position, spending trajectory, and progress toward potential regulatory approval.

Earnings Expectations

Consensus estimates point to a continued net loss for the third quarter of 2026, with revenue expected near $5 million. Because the company completed a 1-for-80 reverse stock split in September 2026, per-share figures vary across data providers and should be compared carefully. On a pre-split basis, consensus loss expectations for the quarter have ranged from roughly $0.05 to $0.14 per share.

For context, Gossamer Bio reported second-quarter 2026 revenue of $9.24 million, well above the consensus of about $3.6 million, and a loss of $0.08 per share that beat the $0.12 consensus loss. The prior quarter told a different story: first-quarter 2026 revenue of $16.95 million far exceeded the roughly $4.7 million expected, but the loss of $0.20 per share missed the $0.17 consensus.

Beyond headline figures, investors will focus on the cash balance, research and development (R&D) and general and administrative (G&A) expenses, and any updated commentary on the NDA submission timeline, which management has targeted for September 2026 with potential approval in the third quarter of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotech names like Gossamer Bio alongside the broader market, the AI Screener offers a structured way to surface actionable ideas.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report remains cautious. Gossamer Bio shares have been highly volatile, reflecting both clinical progress and significant financial uncertainty. After first-quarter results, the stock fell sharply in after-hours trading before partially recovering, underscoring how sensitive the shares are to any signal about the company's runway and regulatory path. The September 2026 reverse stock split was intended to support the share price and exchange listing, but it also highlights the pressure the equity has faced. Investors are weighing a potentially transformative approval path for seralutinib against the risk that the company may need additional capital before reaching a key regulatory milestone.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the regulatory process for seralutinib. Management has said it plans to submit an NDA based on the Phase 3 PROSERA study, supported by confirmatory evidence from the Phase 2 TORREY trial, with a target submission in September 2026. Investors should watch for confirmation of the submission and, later, acceptance by the U.S. Food and Drug Administration (FDA).

Cash runway is the other critical variable. As of March 31, 2026, the company held about $99 million in cash and marketable securities, with management guiding that this funds operations only into the first quarter of 2027. The proposed exchange of convertible notes, which would reduce outstanding debt and extend maturity, depends on high participation from noteholders and remains a key risk.

Finally, investors should monitor operating expenses and the pace of cash burn following the workforce reduction, as well as any update on the paused PH-ILD (pulmonary hypertension associated with interstitial lung disease) program. Together, these factors will shape whether Gossamer Bio can reach a potential approval and commercialization stage without further dilution or financing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations